000 06082nam a22003855i 4500
001 76078
003 ES-MaUEC
005 20230207040208.0
007 cr nn 008mamaa
008 131203s2014 xxu| s |||| 0|eng d
020 _a9781461491057
024 7 _a10.1007/978-1-4614-9105-7
_2doi
050 4 _aRM315
_b.D78 2014 EB
082 0 4 _a615.19
245 0 0 _aDrug Delivery to the Brain :
_bPhysiological Concepts, Methodologies and Approaches
_cedited by Margareta Hammarlund-Udenaes, Elizabeth C.M. de Lange, Robert G. Thorne
260 _aNew York, NY
_bSpringer International Publishing
_c2014
300 _a1 recurso en línea (XX, 731 p.)
_b150 ilustraciones, 126 ilustraciones en color
336 _aTexto (visual)
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
490 1 _aAAPS Advances in the Pharmaceutical Sciences Series
_x2210-7371
_v10
505 0 _aAnatomy and physiology of the blood-brain barriers -- Recent Progress in Blood-Brain Barrier and Blood-CSF Barrier Transport Research: Pharmaceutical Relevance for Drug Delivery to the Brain -- Blood-Brain Barrier (BBB) Pharmacoproteomics: A New Research Field Opened up by Quantitative Targeted Absolute Proteomics (QTAP) -- Drug Metabolism at the Blood-Brain and Blood-CSF Barriers -- Pharmacokinetic Concepts in Brain Drug Delivery -- In vitro models of blood-brain barriers -- In situ and in vivo animal models -- Principles of PET and its Role in Understanding Drug Delivery to the Brain -- PKPD Aspects of Brain Drug Delivery in a Translational Perspective -- Drug Discovery Methods for Studying Brain Drug Delivery and Distribution -- Prediction of Drug Exposure in the Brain from the Chemical Structure -- Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the old to the new Paradigm and Assessment of Drug-Transporter Interactions -- Pharmacoeconomic Considerations in CNS Drug Development -- Intranasal Drug Delivery to the Brain -- Blood-To-Brain Drug Delivery using Nanocarriers -- Development of new Protein Vectors for the Physiologic Delivery of Large Therapeutic Compounds to the CNS- CNS Gene Therapy Utilizing Intravenously Administered Viral Vectors -- Neurosurgical Approaches: Drug Infusion Directly into the Parenchyma or Cerebrospinal Fluid -- Osmotic Opening of the BBB for Drug Treatment of Brain Tumors (Focus on Methodological Issues) -- Emerging Engineering Technologies for Opening the BBB -- Disease Influence on BBB Transport in Inflammatory Disorders -- Disease Influence on BBB Transport in Neurodegenerative Disorders -- Drug Delivery in the Context of Stroke and Brain Trauma -- Which Drug or Drug Delivery Method can change Clinical Practice for Brain Tumor Therapy?.
520 _aThis book describes the different approaches for drug delivery to the brain with an emphasis on the physiology of the blood-brain barrier (BBB) and the governing principles and concepts for drug delivery across the BBB. It contains cutting-edge methods for studying drug delivery and administering drugs into the brain. The book also explores different approaches for predicting human brain concentrations as well as the influence of disease and drug industry perspectives. In addition to wide-ranging coverage of physiological concepts relevant to central nervous system (CNS) drug delivery, a detailed review of brain structure, function, blood supply and fluids is also provided. In each chapter, descriptions of future challenges and unresolved questions are combined with points for discussion. This unique combination of material makes this book a valuable resource for students and for established academic and industry scientists looking to learn about state-of-the-art drug delivery research. It is also a source for stimulating new ideas among experts already performing CNS drug delivery research or working in related areas. Â{u0361}rgareta Hammarlund-Udenaes (Ph.D.) is a Professor in Pharmacokinetics and Pharmacodynamics (PK/PD) at Uppsala University and the Head of the Translational PK/PD Group. Her research is focused on studying pharmacokinetic aspects of BBB transport of drugs in relation to CNS effects, and it has led to the development of new concepts and methods within the BBB transport area, focusing on unbound drug relationships. ÂŬizabeth C.M. de Lange (Ph.D.) is Head of the Target Site Equilibration Group at the Division of Pharmacology of the Leiden Academic Center for Drug Research (LACDR). research program focuses on the development of generally applicable predictive PK/PD models on CNS drugs using advanced in vivo animal models and mathematical modeling techniques, with a number of recent successes. Â{u04AF}bert G. Thorne (Ph.D.) is an Assistant Professor in Pharmaceutical Sciences at the University of Wisconsin-Madison School of Pharmacy. He was previously a research scientist and faculty member in the Department of Physiology & Neuroscience at the New York University School of Medicine. His research focuses on diffusive and convective transport within the CNS and the development, refinement and optimization of strategies for delivering biologics into the brain.
942 _2lcc
_cLE
988 _aEBOOK, EBSPRINGERrevisado
650 7 _9139882
_aPsicofarmacología
_0comprobar BNE19900978082
_2embne
700 1 _aLange, Elizabeth C. M de
_eeditor literario
_0Local
_984936
700 1 _aThorne, Robert G
_eeditor literario
_984937
_0Local
700 1 _aHammarlund-Udenaes, Margareta
_eeditor literario
_984938
_0Local
830 0 _aAAPS Advances in the Pharmaceutical Sciences Series
_x2210-7371
_v10
_9133175
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-9105-7
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907 _a.b12816966
_b10-10-17
_c01-10-14
998 _am
_a_alco
_a_vill
_b26-05-17
_cm
_dz
_eh
_feng
_gxxu
_h0
945 _aRM315 .D78 2014 EB
_g1
_ieBOOK
_j0
_lmae
_o-
_pEUR0.00
_q-
_r-
_sb
_t15
_u0
_v0
_w0
_x0
_y.i11546189
_z06-04-17
999 _c76078
_d76078
_x1